Electronic Optimization of Heteroleptic Ru(II) Bipyridine Complexes by Remote Substituents: Synthesis, Characterization, and Application to Dye-Sensitized Solar Cells

We prepared a series of new heteroleptic ruthenium(II) complexes, Ru(NCS)2LL′ (3a−3e), where L is 4,4′-di(hydroxycarbonyl)-2,2′-bipyridine and L′ is 4,4′-di(p-X-phenyl)-2,2′-pyridine (X = CN (a), F (b), H (c), OMe (d), and NMe2 (e)), in an attempt to explore the structure−activity relationships in their photophysical and electrochemical behavior and in their performance in dye-sensitized solar cells (DSSCs). When substituent X is changed from electron-donating NMe2 to electron-withdrawing CN, the absorption and emission maxima reveal systematic bathochromic shifts. The redox potentials of these dyes are also significantly influenced by X. The electronic properties of the dyes were theoretically analyzed using density functional theory calculations; the results show good correlations with the experimental results. The solar-cell performance of DSSCs based on dye-grafted nanocrystalline TiO2 using 3a−3e and standard N3 (bis[(4,4′-carboxy-2,2′-bipyridine)(thiocyanato)]ruthenium(II)) were compared, revealing substantial dependences on the dye structures, particularly on the remote substituent X. The 3d-based device showed the best performance: η = 8.30%, JSC = 16.0 mA·cm−2, VOC = 717 mV, and ff = 0.72. These values are better than N3-based device

Additional file 1: of The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography

Table S1. Baseline demographic and clinical characteristics of the patients. Table S2. Baseline demographic and clinical characteristics of the patients. Table S3. Table S4. Lesion characteristic and initial QCA of the total lesions. Table S5. Initial and final Diameter Stenosis according to Diabetes and Lesion type. Figure S1. Histogram of DS progression and velocity of DS progression. (DOCX 204 kb

Results of linear mixed models for repeated measures of cardiac biomarkers for 72 h following procedure.

Results of linear mixed models for repeated measures of cardiac biomarkers for 72 h following procedure.</p

Additional file 1 of Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus

Additional file 1: Table S1. List of investigators and participating centers of the Grand Drug-Eluting Stent registry. Table S2. Comparison of baseline characteristics between DM and non-DM population. Table S3. Subgroup analysis for the risk of patient-oriented composite outcome after complete revascularization compared to incomplete revascularization in the DM population. Table S4. Subgroup analysis for the risk of target lesion failure after complete revascularization compared to incomplete revascularization in the DM population. Table S5. Clinical outcomes according to the residual SYNTAX score in DM population. Figure S1. Study flow. Figure S2. Comparisons of clinical outcomes between DM and non-DM populations. Figure S3. Subgroup analysis for the risk of clinical outcomes after complete revascularization compared to incomplete revascularization in DM population. Figure S4. Reasonable level of revascularization in DM population. Figure S5. Annual trends of HbA1c (%) level among DM population

Changes in arterial oxygenation, pulse oxygen saturation, and cerebral oximetry in patients receiving a fraction of inspired oxygen of 0.3 or 0.8 during transcatheter aortic valve implantation.

FIO2, fraction of inspired oxygen; PaO2, arterial partial pressure of oxygen; SaO2, arterial oxygen saturation; SpO2, pulse oxygen saturation; ScrbO2, mean cerebral oxygen saturation.</p

Table_1_Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation.docx

BackgroundSystemic inflammatory response syndrome (SIRS) is a systemic insult that has been described with many interventional cardiac procedures. The outcomes of patients undergoing transcatheter aortic valve implantation (TAVI) are thought to be influenced by this syndrome not only on short-term, but also on long-term.ObjectiveWe assessed the association of SIRS to different clinical, echocardiographic, and computed tomographic (CT) outcomes after TAVI.MethodsTwo hundred and twenty-four consecutive patients undergoing TAVI were enrolled in this study. They were assessed for the occurrence of SIRS within the first 48 h after TAVI. Patients were followed-up for short- and long-term clinical outcomes. Serial echocardiographic follow-ups were conducted at 1-week, 6-months, and 1-year. CT follow-up at 1 year was recorded.ResultsEighty patients (36%) developed SIRS. Among different parameters, only pre-TAVI total leucocytic count (TLC), pre-TAVI heart rate, and post-TAVI systolic blood pressure independently predicted the occurrence of SIRS. The incidence of HALT was not significantly different between both groups, albeit higher among SIRS patients (p = 0.1) at 1-year CT follow-up. Both groups had similar patterns of LV recovery on serial echocardiography. Long-term follow-up showed that all-cause death, cardiac death, and re-admission for heart failure (HF) or acute coronary syndrome (ACS) were significantly more frequent among SIRS patients. Early safety and clinical efficacy outcomes were more frequently encountered in the SIRS group, while device-related events and time-related valve safety were comparable.ConclusionAlthough SIRS implies an early acute inflammatory status post-TAVI, yet its clinical sequelae seem to extend to long-term clinical outcomes.</p

Valve characteristics and procedural variables in patients undergoing transfemoral transcatheter aortic valve implantation.

Valve characteristics and procedural variables in patients undergoing transfemoral transcatheter aortic valve implantation.</p

S2 File -

BackgroundOxygen therapy is used in various clinical situation, but its clinical outcomes are inconsistent. The relationship between the fraction of inspired oxygen (FIO2) during transcatheter aortic valve implantation (TAVI) and clinical outcomes has not been well studied. We investigated the association of FIO2 (low vs. high) and myocardial injury in patients undergoing TAVI.MethodsAdults undergoing transfemoral TAVI under general anesthesia were randomly assigned to receive FIO2 0.3 or 0.8 during procedure. The primary outcome was the area under the curve (AUC) for high-sensitivity cardiac troponin I (hs-cTnI) during the first 72 h following TAVI. Secondary outcomes included the AUC for postprocedural creatine kinase-myocardial band (CK-MB), acute kidney injury and recovery, conduction abnormalities, pacemaker implantation, stroke, myocardial infarction, and in-hospital mortality.ResultsBetween October 2017 and April 2022, 72 patients were randomized and 62 were included in the final analysis (n = 31 per group). The median (IQR) AUC for hs-cTnI in the first 72 h was 42.66 (24.82–65.44) and 71.96 (35.38–116.34) h·ng/mL in the FIO2 0.3 and 0.8 groups, respectively (p = 0.066). The AUC for CK-MB in the first 72 h was 257.6 (155.6–322.0) and 342.2 (195.4–485.2) h·ng/mL in the FIO2 0.3 and 0.8 groups, respectively (p = 0.132). Acute kidney recovery, defined as an increase in the estimated glomerular filtration rate ≥ 25% of baseline in 48 h, was more common in the FIO2 0.3 group (65% vs. 39%, p = 0.042). Other clinical outcomes were comparable between the groups.ConclusionsThe FIO2 level did not have a significant effect on periprocedural myocardial injury following TAVI. However, considering the marginal results, a benefit of low FIO2 during TAVI could not be ruled out.</div

Postprocedural variables in patients received fraction of inspired oxygen 0.3 or 0.8 during transfemoral transcatheter aortic valve implantation.

Postprocedural variables in patients received fraction of inspired oxygen 0.3 or 0.8 during transfemoral transcatheter aortic valve implantation.</p

S1 File -

BackgroundOxygen therapy is used in various clinical situation, but its clinical outcomes are inconsistent. The relationship between the fraction of inspired oxygen (FIO2) during transcatheter aortic valve implantation (TAVI) and clinical outcomes has not been well studied. We investigated the association of FIO2 (low vs. high) and myocardial injury in patients undergoing TAVI.MethodsAdults undergoing transfemoral TAVI under general anesthesia were randomly assigned to receive FIO2 0.3 or 0.8 during procedure. The primary outcome was the area under the curve (AUC) for high-sensitivity cardiac troponin I (hs-cTnI) during the first 72 h following TAVI. Secondary outcomes included the AUC for postprocedural creatine kinase-myocardial band (CK-MB), acute kidney injury and recovery, conduction abnormalities, pacemaker implantation, stroke, myocardial infarction, and in-hospital mortality.ResultsBetween October 2017 and April 2022, 72 patients were randomized and 62 were included in the final analysis (n = 31 per group). The median (IQR) AUC for hs-cTnI in the first 72 h was 42.66 (24.82–65.44) and 71.96 (35.38–116.34) h·ng/mL in the FIO2 0.3 and 0.8 groups, respectively (p = 0.066). The AUC for CK-MB in the first 72 h was 257.6 (155.6–322.0) and 342.2 (195.4–485.2) h·ng/mL in the FIO2 0.3 and 0.8 groups, respectively (p = 0.132). Acute kidney recovery, defined as an increase in the estimated glomerular filtration rate ≥ 25% of baseline in 48 h, was more common in the FIO2 0.3 group (65% vs. 39%, p = 0.042). Other clinical outcomes were comparable between the groups.ConclusionsThe FIO2 level did not have a significant effect on periprocedural myocardial injury following TAVI. However, considering the marginal results, a benefit of low FIO2 during TAVI could not be ruled out.</div